April 3, 2013 Press Release Mitsubishi Tanabe Pharma Corporation Launch of BindRen® for Treatment of Hyperphosphatemia in Germany and Austria Osaka, Japan, April 3, 2013—Mitsubishi Tanabe Pharma Corporation (President

Source URL: www.mt-pharma.co.jp

• Kidney diseases
• Nephrology
• Phosphate binders
• Hyperparathyroidism
• Secondary hyperparathyroidism
• Dialysis
• Hyperphosphatemia
• Phosphorus
• Chronic kidney disease
• Medicine
• Chemistry
• Health

May 8, 2012 Mitsubishi Tanabe Pharma Corporation Notice of Dividend of Retained Earnings Osaka, Japan, May 8, [removed]Mitsubishi Tanabe Pharma Corporation (President & CEO:

Source URL: www.mt-pharma.co.jp

• Dividend
• Generally Accepted Accounting Principles
• Business
• Ex-dividend date
• Retained earnings
• Money
• Dividends
• Financial ratios
• Finance

June 14, 2013 Press release: Mitsubishi Tanabe Pharma Corporation Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE® Tablets: Selective β1 Blocker

Source URL: www.mt-pharma.co.jp

• Cardiology
• Chemistry
• Beta blockers
• Atrial fibrillation
• Bisoprolol
• Antiarrhythmic agents
• Systole
• Sotalol
• Cardiac dysrhythmia
• Alcohols
• Circulatory system

June 1, 2012 Press Release Mitsubishi Tanabe Pharma Corporation Termination of License Agreement with Cytochroma for MT[removed]Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism

Source URL: www.mt-pharma.co.jp

• Mitsubishi
• Hyperparathyroidism
• Mitsubishi Chemical Holdings
• Economy of Japan
• Mitsubishi companies
• Secondary hyperparathyroidism

June 30, 2014 Press release: Mitsubishi Tanabe Pharma Corporation Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS)

Source URL: www.mt-pharma.co.jp

April 1, 2013 PRESS RELEASE Mitsubishi Tanabe Pharma Corporation U.S. FDA Approves Canagliflozin (TA[removed]for the Treatment of Adult Patients with Type 2 Diabetes

Source URL: www.mt-pharma.co.jp

• Diabetes mellitus
• SLC5A2
• Anti-diabetic medication
• Diabetes
• Health
• Medicine

September 20, 2012 Press Release Mitsubishi Tanabe Pharma Corporation Launch of "Simponi®”, a human TNFα monoclonal antibody in Indonesia Osaka, Japan, September 20, [removed]Mitsubishi Tanabe Pharma Corporation (Pres

Source URL: www.mt-pharma.co.jp

• Arthritis
• Pharmacology
• Centocor
• Monoclonal antibodies
• Autoimmune diseases
• Golimumab
• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Medicine
• Health
• Rheumatology

June 16, 2014 Press release Mitsubishi Tanabe Pharma Corporation Positive Phase 3 Results of Canagliflozin in Japanese Patients with Type 2 Diabetes at American Diabetes Association

Source URL: www.mt-pharma.co.jp

• Medicine
• Diabetes management
• Glycated hemoglobin
• Diabetes mellitus type 2
• Diabetes mellitus
• Diabetes
• Endocrine system
• Health

August 1, 2013 Press release: Mitsubishi Tanabe Pharma Corporation Notice regarding the reorganization of Mitsubishi Tanabe Pharma Factory Ltd.’s domestic production sites and the conclusion of a basic agreement regard

Source URL: www.mt-pharma.co.jp

• Mitsubishi Motors
• Mitsubishi
• Pharmaceutical industry in India
• Tanabe
• Wakayama
• Mitsubishi Pharma
• Economy of Japan
• Mitsubishi companies
• Economy of Asia

October 26, 2012 Press Release The Research Foundation for Microbial Diseases of Osaka University Mitsubishi Tanabe Pharma Corporation Launch of TETRABIK

Source URL: www.mt-pharma.co.jp

• Microbiology
• Health
• Poliomyelitis
• Virology
• Vaccines
• Polio vaccine
• Pertussis
• Tetanus
• ATC code J07
• Medicine
• Vaccination
• Bacterial diseases